MDM2 regulates estrogen receptor α and estrogen responsiveness in breast cancer cells

Department of Veterinary Physiology and Pharmacology, Texas A&M University, 4466 TAMU, Veterinary Research Building 410, College Station, Texas 77843-4466, USA.
Journal of Molecular Endocrinology (Impact Factor: 3.08). 04/2011; 46(2):67-79. DOI: 10.1677/JME-10-0110
Source: PubMed


Murine double minute clone 2 (MDM2) is a multifunctional protein, which modulates nuclear receptor-mediated transactivation. In this study, we show that MDM2 significantly enhanced estrogen receptor α (ERα) and ERα/specificity protein-mediated transactivation in MCF-7 and ZR-75 breast cancer cells. This was demonstrated by both MDM2 overexpression and knockdown experiments by RNA interference. ERα interacted with wild-type MDM2 and deletion mutants of MDM2 containing amino acids 1-342 (C-terminal deletion) and 134-490 (N-terminal deletion), but not 134-342. In contrast, only wild-type but not mutant MDM2 enhanced ERα-mediated transactivation. Protein-protein interactions in vitro were 17β-estradiol (E(2)) independent, whereas fluorescent resonance energy transfer experiments in living cells showed that E(2) enhanced ERα-MDM2 interactions. Subsequent RNA interference and mammalian two-hybrid experiments suggested that MDM2 did not directly interact with endogenous coactivators such as the steroid receptor coactivators but played a role in enhancing ERα-mediating gene expression and estrogen responsiveness through interactions with ERα.

Download full-text


Available from: Kyounghyun Kim, Apr 29, 2015
23 Reads
  • Source
    • "MDM2 TG + GG plus BCL2 CA + AA combined genotype was associated with increased risk of CM only in men in our study, suggesting a synergic action of MDM2 and BCL2 genes in CM [14] [19] [20]. Again, exposure of subjects to sex hormones could make difference in P53 [39] [62], MDM2 [36] [63], BAX [39] [64], and BCL2 [35] "
    [Show abstract] [Hide abstract]
    ABSTRACT: The P53 Arg72Pro, MDM2 c.+309T>G, BAX c.-248G>A, and BCL2 c.-717C>A polymorphisms have variable roles in the apoptosis pathways. To clarify the roles of these polymorphisms in the risk for cutaneous melanoma (CM). Genomic DNA of 200 CM patients and 215 controls was analyzed by PCR-RFLP. In women, the frequencies of BAX GG (83.0% vs. 71.0%, P=0.04), BCL2 AA (32.0% vs. 15.0%, P=0.003), P53 ArgArg plus BAX GG (84.9% vs. 63.2%, P=0.01), P53 ArgArg plus BCL2 AA (37.0% vs. 13.1%, P=0.003), BAX GG plus BCL2 AA (70.3% vs. 33.3%, P=0.001), MDM2 GG plus BAX GG plus BCL2 AA (27.3% vs. 3.7%, P=0.03), and P53 ArgArg plus MDM2 GG plus BAX GG plus BCL2 AA (33.3% vs. 5.6%, P=0.04) genotypes were higher in patients than in controls. Female carriers of the respective genotypes were under 1.98 (95% CI: 1.01-3.91), 2.87 (95% CI: 1.43-5.77), 3.48 (95% CI: 1.34-9.04), 4.23 (95% CI: 1.63-10.96), 6.04 (95% CI: 2.10-17.37), 25.61 (95% CI: 1.29-507.24), and 25.69 (95% CI: 1.11-593.59)-fold increased risks for CM than others, respectively. In men, the frequencies of BCL2 CA+AA (83.0% vs. 67.6%, P=0.01) and MDM2 TG+GG plus BCL2 CA+AA (94.2% vs. 68.3%, P=0.003) genotypes were higher in patients than in controls. Male carriers of the respective genotypes were under 2.43 (95% CI: 1.23-4.82) and 9.22 (95% CI: 2.16-39.31)-fold increased CM risks than others, respectively. The data suggest for the first time that P53 Arg72Pro, MDM2 c.+309T>G, BAX c.-248G>A, and BCL2 c.-717C>A polymorphisms, enrolled in apoptosis pathways, constitute distinct determinants of CM in women and men.
    Journal of dermatological science 01/2014; 74(2). DOI:10.1016/j.jdermsci.2013.12.010 · 3.42 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The biological actions of estrogen are mediated via estrogen receptors ERα and ERβ. Yet, other cellular signaling events that also impact ER functions have an important role in breast carcinogenesis. Here, we show that activation of ErbB2/ErbB3 tyrosine kinase receptors with growth factor heregulin-β prompts ERβ degradation by the 26S proteasome, a mechanism that requires the coactivator cAMP response element-binding (CREB)-binding protein (CBP). We found that CBP promotes ERβ ubiquitination and degradation through enhancement of the PI3-K/Akt pathway by heregulin-β, an effect potentiated by a negatively charged hinge region of ERβ. Activated Akt triggered the recruitment of E3 ubiquitin ligase Mdm2 to ERβ, which was further stabilized by CBP, resulting in ERβ poly-ubiquitination. Mutation of CBP Thr-1872 or Mdm2 Ser-186/188 Akt sites resulted in a dissociation of the ERβ-CBP-Mdm2 complex and reduced ERβ turnover. We found that the decrease in ERβ induced by heregulin-β was associated with reduced target gene promoter occupancy and enhanced proliferation of breast cancer cells. However, knockdown of Mdm2 restored endogenous ERβ levels resulting in reduction of breast cancer cell growth. These studies identify a tripartite Akt-regulated phosphorylation mechanism that functions to hamper normal ERβ activity and turnover through the concerted actions of CBP and Mdm2 in response to growth factor signaling pathways in breast cancer cells.Oncogene advance online publication, 20 February 2012; doi:10.1038/onc.2012.19.
    Oncogene 02/2012; 32(1). DOI:10.1038/onc.2012.19 · 8.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The ubiquitin-proteasome system (UPS) harbors elaborated protein quality control systems in eukaryotic cells. Recently, the UPS is emerging as an important regulator in controlling the magnitude and the duration of the steroid hormone responses. Upon steroid hormone stimuli, their cognate steroid receptors, including androgen receptor (AR) and estrogen receptor (ER), not only mediate transcriptional activation, but also undergo ubiquitination and consequent proteasomal degradation. Many reports have strongly suggested that UPS machinery, particularly the E3 ubiquitin ligases, are closely involved in the receptor-mediated gene expression regulation. Both ligand-dependent and -independent recruitment of E3 ubiquitin ligases often prompt the degradation of target steroid receptors and correct transcription activation. Here, we review that the deep mechanistic connections between AR and ER-dependent transcription and the UPS for the correct expression of target genes. We also emphasize that this regulatory system has a significant potential for future clinical application, including the treatment of breast and prostate cancers by facilitating the degradation of related hormone receptors.
    Archives of Pharmacal Research 03/2012; 35(3):397-407. DOI:10.1007/s12272-012-0301-x · 2.05 Impact Factor
Show more